A trial of enfortumab vedotin (ASG-22ME) in combination with checkpoint inhibitor (CPI)

Trial Profile

A trial of enfortumab vedotin (ASG-22ME) in combination with checkpoint inhibitor (CPI)

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jun 2017 New trial record
    • 05 Jun 2017 According to a Seattle Genetics media release, this trial this trial is expected to initiate later 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top